Znane i nowe cele terapeutyczne w raku jajnika Katarzyna Kamińska, Aleksandra Klemba
Transkrypt
Znane i nowe cele terapeutyczne w raku jajnika Katarzyna Kamińska, Aleksandra Klemba
Znane i nowe cele terapeutyczne w raku jajnika Katarzyna Kamińska, Aleksandra Klemba Klinika Onkologii Laboratorium Onkologii Molekularnej Molecular Mechanisms of Cancer ECMs Cytokines Oncogene Growth Factors Tumor Suppressor Energy Depletion Hormones GRB2 C3G Crk GRB2 SOS Oncogene SOS Oncogene EPAC1 NF1 Tumor Suppressor Src cAMP Oncogene Gb Gg Ga PI3K SHC RasGAP MEK1/2 Akt Abl ATR Tumor Suppressor Tumor Suppressor Chk2 CcFo Ju s Oncogene n Chk1 BclXL PUMA BIM BAK CDC25A A CD Cc HP Oncogene CD K2 nE Vcyclin Oncogene p53 Oncogene C2 Regulation P18(INK4C) E6 CTumor Wee1 Tumor VHL Fo Suppressor Oncogene CD P19(INK4D) Suppressor P21(CIP1) s cK4, MD Tumor Cc WNT, Ptc, BMP Ju Oncogene 6 Cell cyclie M2 Suppressor nD Regulation n Regulation MIZ P15(INK4B) Cc Gli Tumor 1 CD MA P14(ARF) Suppressor nE Oncogene P16(INK4A) K2 My X P27(KIP1) Angogenesis Tumor HIF1a c P21(CIP1) Tumor Suppressor Tumor Oncogene Suppressor MIZ Suppressor Cell Survival 1 SMAD SO RA 2,3,4 Cell Survival RBPJ-k X R SMAD2,3 p300 HAT1 CBP CIAP Caspase9 Apoptosis APAF1 Caspase3,6,7 MKK-7 SMAD 1,5,8 TCF3,4 BID Caspase8,10 MKK3;6 n SMAD6 SuFu Fu NLK Gli SMAD4 SMAD2,3 TAB1TAK1 FLi P Oncogene Suppressor APC AXIN Ctn n NUMB G-Proteins TAB2 SMAD SMAD4 1,5,8 Tumor Oncogene bTumor Suppressor CytoC Ctn Oncogene Microtubules Gli BA X Oncogene SMAC p38 LEF1 b- tBID MMP NF-k B HP Tumor Oncogene VSuppressor E7 DNA Breakage Rb E2Fs Ladder-Like DNA CDC25 B/C Bcl2Suppressor Noxa Fo x01 Cell Survival Cyclins, CDKs and CKls Gene Expression Aur ora Oncogene Tumor Tumor Ik-Bs Suppressor BAD Cc nD Regulation and Oncogenesis BRCA1 C-Raf p53 Oncogene cCJuOncogene Fo Cell n s cycle NBS1 DNA-PK MD M2 Oncogene mTOR Pathway JNK FANCD2 ATM ERK1/2 PAK1 GSK3 Autophagy and Translation Elk Rad51, 52 Tumor Suppressor Ra c Oncogene mTORC1 Cell Proliferation DNA Repair Akt RHEB ERK1/2 JNK Ra s Oncogene PTEN Tumor Suppressor Oncogene Akt Signaling Oncogene MP1 ERK1/2 HIPK2 RalGAP PI3K c-Raf TSC1/2 Oncogene MP1 Oncogene RasGRF MEK1/2 PI3K RasGEF SynGAP PDK-1 RalA/B PIP3 PKC C a 2 RasGRP + Oncogene RalGEF Oncogene CamK2 PI3K AMPK Rap IP3 LKB1 PIP3 Oncogene Oncogene DAG Fy n Oncogene Rh o Oncogene BRaf PKA GSK3b FADD ASK1 SMAD7 TAB1,2 TAK1 MKK-7 TRADD SMAD7 SMAD 1,5,8 ERK SMAD2/3 Dsh Oncogene b- Ctn a-Ctnn ADAM 17/ TACE n WN T1 Tumor Suppressor Src P120 Ctn Frizz ied WNT5A Tumor Suppressor Ra s Oncogene BMPs Cd2+ TGFb Wpływ beta endorfiny na proliferaję komórek rakowych AlamarBlue OvBH1 lamraraa jaja Ca-1 er lamraraa END β edrfa Wyniki analizy mikromacierzy ekspresyjnej Bezpośredni wpływ β-endorfiny na komórki nowotworowe skutkuje zmianami w ekspresji genów związanych z podziałami komórkowymi (proliferacją) oraz przyleganiem (adhezją) komórek, co przekłada się na proces nowotworzenia i przerzutowania. Dodatkowo, β-endorfina wpływa na ścieżki przekazywania sygnałów wewnątrz komórki, odpowiedzialnych za stan zapalny. Nowotwór jajnika – typy histologiczne A o granicznej złośliwości B surowiczy C endometrioidalny D jasnokomórkowy E, F śluzowy Lancet2014; 384: 1376–88 Odpowiedź na leczenie w raku jajnika Różnice molekularne a odpowiedź na terapię Int J Clin Exp Pathol. 2014 Mar 15;7(4):1502-13. Szlak Nrf2–Keap1 PLoS One. 2014 Dec 23;9(12) Znane cele terapeutyczne w raku jajnika cz.1 http://www.spandidos-publications.com/or/28/2/395 Znane cele terapeutyczne w raku jajnika cz.2 vintafolide Vintafolide http://www.spandidos-publications.com/or/28/2/395 LY2606368 LY2606368 Potencjalny cel terapeutyczny w raku jajnika ARID1A Proliferacja Transformacja onkogenna Apoptoza Inwazyjność Angiogeneza Pluripotencja Nowotworowe komórki macierzystopodobne http://hylostet.pl/igm/article/27/ Marker Method CD133 percentage of Association No correnpondence was found. Sample size Ref. 41 samples of OC Ferriadin a 2008 50 samples stained positive for CD133. No prognostic information Expression of both markers was correlated with reduced disease free survival overall survival on cancer patients 160 samples with stage III, IV OC Ferrandin a 2009 56 stage III,IV samples of epithelial OC Silva 2011 CD133-1+ /CD133-2 CD133 Immunostaining of CD133-1+ cells CD133/ ALDH Tissue microarray, immunofluorescenc e CD133 Tissue microarray Expression (>0% of slide) found in 31% of cancers. CD133 expression was associated with: high-grade serous carcinoma (p=0.035) late-stage disease (p<0.001) • ascites level (p=0.010) non-response to chemotherapy (p=0.023) shorter overall survival time (p=0.007) shorter disease-free survival time (p<0.001) CD133 expression was an independent predictor of shorter disease-free survival time (p=0.024). 400 ovarian carcinomas samples Zhang 2012 Nestin, but not CD133 Immunohistochemical staining Nestin-positive (in comparison to negative cases) correlated cisplatin chemotherapy resistance (55.0% vs. 20.1%, p=0.001) shorter overall survival (p=0.001) Nestin expression was an independent predictor of shorter overall survival time (HR=2.501, p=0.007). 123 samples from stage III/IV serous ovarian carcinoma patients Qin 201 ALDH1, Indirect CD44 Immunohistochemic al staining Patients with higher ALDH1 expression (>50%) had (compared with those with lower ALDH1): poor overall survival (p=0.004) yielded an odds ratio of death of 2.43 (95% CI = 1.12 to 5.28) ALDH1 expression correlated with CD44 expression. 84 samples of OC Wang 2012 CD44+/ CD24- Percentage of such cells found in ascites by FACS Threshold of 25 % CD44+/CD24- ovarian cancer cells found in ascites. Patients with >25 % CD44+/CD24- : were significantly more likely to reoccur (83 vs.14 %, p=0.003) had shorter median progression-free survival (6 vs.18 m, p=0.01) ascites from 19 patients with stage IIIC/IV papillary serous ovarian cancer Meng 2012 Threshold of 25 % CD44+/CD24- ovarian cancer cells found in CD44+ Percentage of CD24- such cells found ascites. Patients with >25 % CD44+/CD24- : in ascites by were significantly more likely to reoccur (83 vs.14 %, p=0.003) FACS had shorter median progression-free survival (6 vs.18 m, p=0.01). CD44+ Tissue CK19 + microarray Immunofluorescene staining CD44 tissue microarray CD117 Immunostaining High frequency cells with CD44+ or CD44+/CK19+ was associated with chemoresistance (p=0.033 and p=0.02, respectively). High frequency of CD44+/CK19+ cells was associated with: short disease-free interval (7.9 vs. 20.9 months, p=0.019) Significant predictor variables were: the frequency of CSLCs (p=0.019) FIGO stage (p=0.037) residual tumor volume and were entered(and 0.005) The frequency of CSLCs was the most promising predictor variable compared with the other 2 variables (hazard ratio=2.344, p=0.052), however no independent significant predictor was found. ascites from Meng E 19 patients with 2012 stage IIIC/IV papillary serous ovarian cancer 33 patients with Liu 2013 epithelial ovarian cancer CD44s expression in 38% of the ovarian carcinoma samples. CD44s expression was associated with: high-grade carcinoma (p=0.013) advanced stage FIGO (III-IV; p<0.001) age at diagnosis less than 60 years (p=0.011) transitional cell carcinoma (p=0.039) CD44s expression was not associated with overall survival (p=0.529) & disease-free survival (p=0.218) There was no statistical difference in CD44s expression between the primary and recurrent ovarian carcinomas 27 paired primary and recurrent ovarian carcinoma samples Zhang 2013 Immunostainings positive for CD117 in 40% of patients. CD117 expression was statistically correlated with resistance to conventional chemtherapy (p=0.027) 25 samples of advanced ovarian serous cancer Lou 2011 Target molecules Inhibitor MEK U0126 CXCR4 AMD3100 ETRA- endothelin receptor A BQ123 CD133 Anti CD133 targeted toxin dCD133KDEL Conventional therapy and fusion cells CD44+ Phenotype of targeted cells Ovca 433 CD133+/ CD44+/CD117+ NOY1 cells (ovaria yolc sac tumor) CD133+ CD133+ NIH:OVCAR5 CD133+ CD44+ cells Claudine-4 Clostridium CD44+ cells perfringens enterotoxin (CPE) CD44 miR-199a Survival-promoting Mitochondria complex of hesokinase II and VDAC 3 bromopyruvate SKOV3 cell of CD44+/CD117+/ALDH1+ CD44 drug delivery system (DDS) CD44+ cells Cells isolated from primary tumors and ascites Finding Reference Inhibited ERK2 activation and partially suppressed cisplatin-induced EMT and Latifi 2011 CSC markers Decreased migration, invasion and colonies formatting capacity Mitsui ETRA inhibition of CSC prevented chemotherapy induced increases in tumor Coffman 2012 stem cells. ETRA inhibition in combination with chemotherapy reduced the formation of tumor spheres. In vitro inhibition of CD133+ cells Skubitz 2013 Fusion cells (FCs) prepared by fusion of dendritic cells and OCIC to specifically target the OCIC subpopulations activated T cells to express elevated levels of IFN-γ with enhanced killing of CD44(+) OVCA cells. Multiple intraperitoneal administrations of sublethal doses of CPE in mice Casagrande 2011 harboring xenografts of chemotherapy-resistant CD44(+) ovarian cancer stem cells had a significant inhibitory effect on tumor progression leading to the cure and/or long-term survival of all treated animals miR-199a significantly increased the chemosensitivity of ovarian CICs to Cheng 2012 cisplatin, pacitaxel, and adriamycin, and reduced mRNA expression of the multidrug resistance gene ABCG2 as compared with miR-199a mutanttransfected and untransfected cells. The expression of stemness markers was also significantly reduced in miR-199a-transfected CICs as compared with miR-199a mutant-transfected and untransfected ovarian cells. Furthermore, xenograft experiments confirmed that miR-199a suppressed the growth of xenograft tumors formed by ovarian CICs in vivo. Pretreated SKOV3 cells exhibited also upregulation of mitochondrial mass Wintzell 2012 and cytochrome c suggesting that targeting survival-promoting mitochondrial complex of hexokinase-II and VDAC might be efficient. Indeed, cell were sensitive to combination treatment of 3-bromopuryvate and significantly lowered doses of cisplatin. nanoscale-based drug delivery system (DDS) containing a modified polypropylenimine (PPI) dendrimer as a carrier; anticancer drug paclitaxel as a cell death inducer; \a synthetic analog of luteinizing hormone-releasing hormone (LHRH) peptide as a tumor-targeting Shah 2013 Podsumowanie Różnice molekularne a odpowiedź na terapię L. Hunakova et al. / Toxicology Letters 230 (2014) 479–486